Among the 113 patients presenting with hormone receptor-positive/HER2-negative breast cancer, the primary tumor was ER and PR-positive in 92 (81.4%) of patients; 15 (13.3%) patients had ER-positive/PR-negative disease. This evidence concerns the gene ERBB2 and breast cancer.